Trozzi, R.
Salvi, M.
Karimi, M.
Minucci, A.
Raspaglio, G.
De Donato, M.
Buttarelli, M.
Piermattei, A.
Vaccaro, L.
Grimaldi, A.
De Santis, R.
Massa, M.
Sillano, F.
Giacò, L.
Mastrantoni, L.
Iacobelli, V.
Camarda, F.
Cesana, M.
Duranti, S.
Sassu, M. C.
Mattogno, P.
Fagotti, A.
Marchetti, C.
Scambia, G.
Nero, C.
Cacchiarelli, D.
Funding for this research was provided by:
AIRC Fellowship for Italy
Italian Ministry of Health, Italian Ministry of University and Research and European Union
Fondazione Telethon Core Grant, Armenise-Harvard Foundation Career Development Award, Italian Ministry of Health, Italian Ministry of University and Research and European Union
Article History
Received: 29 April 2025
Accepted: 17 November 2025
First Online: 19 January 2026
Competing interests
: D.C. is founder, shareholder, and consultant of NEGEDIA S.r.l. G.S. is consultant for AstraZeneca, MSD and Covidien AG, a Medtronic company. G.S. is member of the speakers bureau/honoraria for Olympus Europa SE & CO. KG, Baxter Healthcare SA, Intuitive Surgical Inc., GlaxoSmithKline S.p.A. G.S. is member of the advisory board/advisory committee of TESARO Bio Italy S.r.l. Johnson & Johnson. A.F. has received grants/research support from AstraZeneca and MSD. A.F. is member of the advisory board of GlaxoSmithKline. A.F. is member of the speakers/honorary board of Covidien (Medtronic), GSK, pharmaand GmbH and AbbVie. A.F. is consultant for Oncoinvent AS. C.M. is consultant/advisory board member for Clovis, Pharmamar, GSK, AstraZeneca, AbbVie, pharmaand GmbH and MSD. C.M. has received travel accommodation from Pharmamar and Roche. C.N. is member of the speakers bureau/honoraria for AstraZeneca, GSK, MSD, GH and Illumina. C.N. is member of the advisory board/advisory committee of AstraZeneca and MSD. C.N. has received grants/research support from AstraZeneca and GH. C.N. has received travel accommodation from AstraZeneca, MSD and Illumina.